Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis B news

Show

From To
J&J signs deal with Chinese company for hepatitis B drug

The deal with Sino's Chia Tai Tiaqing Pharmaceutical unit includes an immune-stimulating agent that could potentially be combined with antiviral drugs J&J acquired when it purchased Novira Therapeutics in November. Hepatitis B has been difficult to cure because antiviral medicines that block replication of the virus have proved insufficient at clearing it from the blood. J&J and other researchers believe an assault by components of the immune system will be needed as part of a cure.

Published
08 January 2016
From
Reuters
I am surviving only on 25 per cent of my liver today: Amitabh Bachchan

Bollywood megastar Amitabh Bachchan made a startling revelation about surviving only on 25 per cent of his liver today having lost the rest 75 percent to the deadly Hepatitis B virus. Speaking at the launch of media campaign for on Hepatitis, Amitabh Bachchan recollected how he contracted the disease.

Published
24 November 2015
From
The Indian Express
HIV Drugs Provide Added Benefit of Protecting Against Hepatitis B Virus

A cohort study involving 2,400 men who have sex with men has shown that men with HIV who were treated effectively with HIV therapy — defined as no detectable HIV virus in the blood — were the least likely (80 percent less likely) to get infected with HBV over a median follow-up of approximately 9.5 years, compared with men with HIV who were not on HIV therapy or men who had detectable HIV virus while on HIV therapy.

Published
13 October 2015
From
Johns Hopkins Medicine
ContraVir Reports New Data demonstrating CMX157 to be 60-Fold More Potent Against Hepatitis B Virus than Gilead's Viread®

The Company believes CMX157's lipid-conjugate design clearly differentiates it from tenofovir DF. ContraVir plans to file an investigational new drug (IND) application for CMX157 to treat HBV before year-end 2015. CMX157 benefits from earlier human studies in volunteers under an IND for HIV. ContraVir is focused on a quick evaluation of CMX157 in a Phase 2 clinical study in patients with hepatitis B which it plans to begin in 2016.

Published
06 October 2015
From
Contravir press release
After Curing Hepatitis C, Gilead Works to Vanquish More Viruses

Gilead Sciences Inc., basking in the success of its cure for hepatitis C, is setting ambitious goals to vanquish two other major viral scourges: HIV and hepatitis B.

Published
19 August 2015
From
Bloomberg
China progresses in hepatitis B vaccination, more treatment effort urged

China has won praises from WHO after reaching its goal to control hepatitis B infection among children through immunization ahead of schedule, but more effort is urged for its adult patients.

Published
27 July 2015
From
Xinhua
Drug Resistance Common Among European Patients With Chronic Hepatitis B

Rates of lamivudine resistance are high among patients with chronic hepatitis B (CHB) infection across Europe, with many patients developing cross-resistance to entecavir, according to a new report.

Published
14 July 2015
From
Medscape
Hepatitis B and C - An Action Plan for Saving Lives in Europe

Last year, leading experts, institutions, patient organisations and pharmaceutical industry representatives met and agreed that the major recommendations produced between 2011 and 2014 should be compiled into one comprehensive document, to make it easier for policy makers, decision makers, civil society organisations and healthcare institutions to tackle viral hepatitis effectively.

Published
20 May 2015
From
European Liver Patients Association
Starved T cells allow hepatitis B to silently infect liver

Hepatitis B stimulates processes that deprive the body’s immune cells of key nutrients that they need to function, finds new UCL-led research funded by the Medical Research Council and Wellcome Trust. The work helps to explain why the immune system cannot control hepatitis B virus infection once it becomes established in the liver, and offers a target for potential curative treatments down the line.

Published
14 May 2015
From
University College London press release
Cancer drug shows promise as cure for hepatitis B

A potential cure for hepatitis B virus infections has been found with a promising new treatment proving 100 per cent successful in eliminating the infection in preclinical models. Australian patients are now the first in the world to have access to the potential treatment -- a combination of an antiviral drug and an anti-cancer drug -- which is in phase 1/2a clinical trials.

Published
21 April 2015
From
Science Daily

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.